Risks of oral anticoagulants: Analysis of adverse drug reactions reported to the Portuguese National Pharmacovigilance System
Pharmacology Research & Perspectives · 2024
DOI: 10.1002/prp2.1235 ↗Kurz gefasst
Fachartikel in der Zeitschrift Pharmacology Research & Perspectives, 2024. Verfasst von Ana Sofia Martins und 2 weiteren Autor:innen. Beteiligte Einrichtung: Health Sciences Faculty, University of Beira Interior, Covilhã, Portugal. Hauptthemen laut MEDLINE: Pharmacovigilance, Anticoagulants, Adverse Drug Reaction Reporting Systems. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 42 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: INFARMED-National Authority of Medicines and Health Products, I.P., Pharmacovigilance Unit of Beira Interior, FCT.
Abstract (Originalsprache)
Cardiovascular diseases are the leading cause of death globally, making the use of oral anticoagulants for prevention increasingly important. Historically, warfarin has played a significant role in this context. In recent years, introduction of new oral anticoagulants, such as rivaroxaban, apixaban, dabigatran, and edoxaban, has been seen. This study evaluates the risk associated with the use of oral anticoagulants by analyzing spontaneous adverse drug reactions reported to the Portuguese Pharmacovigilance System from 2012 to 2021. The study includes 951 adverse drug reactions reports, with the majority ( n = 770; 80.97%) classified as serious. Of the 770 serious adverse drug reactions reports, the most commonly reported seriousness criterion was “Clinically Important” ( n = 350; 45.45%). In terms of demographics, there was a higher reporting rate among the elderly population, with a greater prevalence of females. The System Organ Class group with the highest number of adverse drug reactions was “Gastrointestinal disorders,” with the most commonly reported Preferred Term being “Gastrointestinal hemorrhage,” and dabigatran was the most frequently reported drug. In summary, oral anticoagulants have adverse drug reactions that require continuous monitoring. Accurate identification and monitorization of adverse drug reactions is an important starting point to improve drug safety in population.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Health Sciences Faculty, University of Beira Interior, Covilhã, Portugal.
- UFBI- Pharmacovigilance Unit of Beira Interior, University of Beira Interior, Covilhã, Portugal.
- CISCS-UBI- Health Sciences Research Centre, University of Beira Interior, Covilhã, Portugal.
ORCID-Profile: Ana Sofia Martins, Cristina Monteiro, Ana Paula Duarte
Förderung
- INFARMED-National Authority of Medicines and Health Products, I.P.
- Pharmacovigilance Unit of Beira Interior
- FCT
- Fundo Europeu deDesenvolvimento Regional
- PORTUGAL 2020
- Programa Operacional do Centro (CENTRO 2020)
- Fundació Catalana de Trasplantament
- Programa Operacional Regional do Centro
Zitieren
APA
Martins, A. S., Monteiro, C., & Duarte, A. P. (2024). Risks of oral anticoagulants: Analysis of adverse drug reactions reported to the Portuguese National Pharmacovigilance System. Pharmacology Research & Perspectives. https://doi.org/10.1002/prp2.1235
Vancouver
Martins AS, Monteiro C, Duarte AP. Risks of oral anticoagulants: Analysis of adverse drug reactions reported to the Portuguese National Pharmacovigilance System. Pharmacology Research & Perspectives. 2024. doi:10.1002/prp2.1235
BibTeX
@article{Martins2024,
author = {Martins, Ana Sofia and Monteiro, Cristina and Duarte, Ana Paula},
title = {Risks of oral anticoagulants: Analysis of adverse drug reactions reported to the Portuguese National Pharmacovigilance System},
journal = {Pharmacology Research & Perspectives},
year = {2024},
doi = {10.1002/prp2.1235}
}
EUVIMED